Phase II study of docetaxel-vinorelbine in platinum-resistant, paclitaxel-pretreated ovarian cancer

Απλή σελίδα τεκμηρίου
dc.contributor.authorAravantinos, G.en
dc.contributor.authorBafaloukos, D.en
dc.contributor.authorFountzilas, G.en
dc.contributor.authorChristodoulou, C.en
dc.contributor.authorPapadimitriou, C.en
dc.contributor.authorPavlidis, N.en
dc.contributor.authorKalofonos, H. P.en
dc.contributor.authorGogas, H.en
dc.contributor.authorKosmidis, P.en
dc.contributor.authorDimopoulos, M. A.en
dc.date.accessioned2015-11-24T18:58:52Z
dc.date.available2015-11-24T18:58:52Z
dc.identifier.issn0923-7534-
dc.identifier.urihttps://olympias.lib.uoi.gr/jspui/handle/123456789/19319
dc.rightsDefault Licence-
dc.subjectAdulten
dc.subjectAgeden
dc.subjectAntineoplastic Agents/pharmacologyen
dc.subjectAntineoplastic Agents, Phytogenic/pharmacologyen
dc.subjectAntineoplastic Combined Chemotherapy Protocols/adverse effects/*therapeutic useen
dc.subjectCisplatin/pharmacologyen
dc.subjectDisease Progressionen
dc.subjectDisease-Free Survivalen
dc.subjectDrug Resistance, Neoplasmen
dc.subjectFemaleen
dc.subjectGranulocyte Colony-Stimulating Factor/administration & dosageen
dc.subjectHumansen
dc.subjectLeukopenia/chemically induceden
dc.subjectMiddle Ageden
dc.subjectNeoplasm Recurrence, Local/*drug therapy/pathologyen
dc.subjectNeutropenia/chemically induceden
dc.subjectOvarian Neoplasms/*drug therapy/pathologyen
dc.subjectPaclitaxel/administration & dosage/*analogs & derivatives/pharmacologyen
dc.subjectProspective Studiesen
dc.subject*Taxoidsen
dc.subjectTreatment Outcomeen
dc.subjectVinblastine/administration & dosage/*analogs & derivativesen
dc.titlePhase II study of docetaxel-vinorelbine in platinum-resistant, paclitaxel-pretreated ovarian canceren
heal.abstractBACKGROUND: This multicenter, prospective phase II study evaluated the safety and efficacy of the combination of docetaxel and vinorelbine in patients with platinum-resistant, paclitaxel-pretreated recurrent ovarian cancer. PATIENTS AND METHODS: Treatment consisted of vinorelbine 25 mg/m(2) as a 20-min i.v. infusion (days 1 and 8), and docetaxel 70 mg/m(2), as a 1-h i.v. infusion (day 8). Granulocyte colony-stimulating factor support was administered prophylactically on days 12-16. Treatment was repeated every 21 days. RESULTS: Forty-six patients were enrolled. The median number of previous chemotherapeutic regimens was one (range 1-3) with a median treatment-free interval of 4.3 months. Four chemotherapy cycles per patient were administered. Almost 75% of the planned doses for both drugs were given. Forty-one patients are evaluable for response. Three patients (6.5% of all patients; 7.3% of evaluable patients) achieved complete response and eight (17.4% and 19.5%, respectively) a partial response to chemotherapy, leading to overall response rates of 23.9% and 26.8%, respectively. Another 34.8% (39.0%) had stable disease. At a median follow-up of 30 months, the median disease-free survival was 13 months, relapse-free survival was 5 months, time to progression was 4.5 months, and overall survival was 9.3 months. Severe toxicities included leukopenia (31%), neutropenia (35%) and febrile neutropenia (20%). CONCLUSIONS: The combination of docetaxel/vinorelbine is an effective regimen with manageable toxicity for the treatment of platinum-resistant, paclitaxel-pretreated ovarian cancer.en
heal.accesscampus-
heal.fullTextAvailabilityTRUE-
heal.identifier.secondaryhttp://www.ncbi.nlm.nih.gov/pubmed/12853352-
heal.identifier.secondaryhttp://annonc.oxfordjournals.org/content/14/7/1094.full.pdf-
heal.journalNameAnn Oncolen
heal.journalTypepeer-reviewed-
heal.languageen-
heal.publicationDate2003-
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικήςel
heal.typejournalArticle-
heal.type.elΆρθρο Περιοδικούel
heal.type.enJournal articleen

Αρχεία

Φάκελος/Πακέτο αδειών

Προβολή: 1 - 1 of 1
Μικρογραφία εικόνας
Ονομα:
license.txt
Μέγεθος:
1.74 KB
Μορφότυπο:
Item-specific license agreed upon to submission
Περιγραφή:
Κατεβάστε

Συλλογές

Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ